Adding Neoadjuvant Nivolumab to Chemo Improved Survival in Resectable NSCLC

(MedPage Today) — CHICAGO — Neoadjuvant nivolumab (Opdivo) plus chemotherapy significantly improved overall survival (OS) compared with chemotherapy alone for patients with resectable non-small cell lung cancer (NSCLC), the phase III CheckMate…